The Effect of Supplemental Docosahexaenoic Acid (DHA) on Neurocognitive Outcomes in Teen and Adult Women With Phenylketonuria(PKU) (PKU&DHA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00892554
Recruitment Status : Completed
First Posted : May 4, 2009
Last Update Posted : December 11, 2015
Atlanta Clinical and Translational Science Institute
Information provided by (Responsible Party):
Rani Singh, Emory University

Brief Summary:
The purpose of this study is to determine if taking supplemental DHA improves measures of processing speed and executive function in teen and adult women with PKU.

Condition or disease Intervention/treatment Phase
Phenylketonuria Dietary Supplement: Docosahexaenoic Acid Dietary Supplement: Corn/soy oil Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: The Impact of Docosahexaenoic Acid on Neuropsychological Status in Females With Phenylketonuria
Study Start Date : June 2007
Actual Primary Completion Date : January 2010
Actual Study Completion Date : January 2010

Arm Intervention/treatment
Experimental: DHA supplementation Dietary Supplement: Docosahexaenoic Acid
Capsules providing 10 mg DHA/kg body weight/day taken once daily
Other Name: DHASCO-S

Placebo Comparator: corn/soy capsule, no DHA Dietary Supplement: Corn/soy oil
Capsules taken once daily

Primary Outcome Measures :
  1. Cognitive processing speed [ Time Frame: 0 months, 4.5 months ]
  2. Executive function [ Time Frame: 0 months, 4.5 months ]

Secondary Outcome Measures :
  1. Plasma and red blood cell DHA concentrations [ Time Frame: 0 months, 4.5 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   12 Years to 50 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Females
  • Phenylketonuria
  • Ages 12 years and older
  • Able to complete neuropsychological testing

Exclusion Criteria:

  • Pregnancy
  • Currently taking DHA supplement

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00892554

United States, Georgia
Emory University
Atlanta, Georgia, United States, 30322
Sponsors and Collaborators
Emory University
Atlanta Clinical and Translational Science Institute
Principal Investigator: Rani H. Singh, PhD, RD, LD Emory University

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Rani Singh, Professor, Emory University Identifier: NCT00892554     History of Changes
Other Study ID Numbers: IRB00002447
First Posted: May 4, 2009    Key Record Dates
Last Update Posted: December 11, 2015
Last Verified: December 2015

Keywords provided by Rani Singh, Emory University:
Docosahexaenoic Acids
Neuropsychological Tests

Additional relevant MeSH terms:
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Amino Acid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases